Top

Published in:

Open Access 01-10-2009 | Original Article

Use of anti-depressants and the risk of fracture of the hip or femur

Authors: M. W. M. van den Brand, M. M. Samson, S. Pouwels, T. P. van Staa, B. Thio, C. Cooper, H. G. M. Leufkens, A. C. G. Egberts, H. J. J. Verhaar, F. de Vries

Published in: Osteoporosis International | Issue 10/2009

Abstract

Summary

Anti-depressants are used largely, but have serious side effects. We show that both selective serotonin re-uptake inhibitors (SSRIs) and tricyclic anti-depressants (TCAs) increase the risk of hip/femur fracture and that this risk is time related and depends on the degree of serotonin transporter inhibition. This should be considered when prescribing anti-depressants to patients.

Introduction

Anti-depressants are known to have serious side effects. We examined the association between the use of anti-depressants and the risk of hip/femur fractures with a special focus on the relation with the degree of 5-hydroxytryptamine transporter (5-HTT) inhibition and the duration of use.

Methods

A case–control study was conducted within the Dutch PHARMO-RLS database. Cases (n = 6,763) were adult patients with a first hip/femur fracture during the study period. For each case, four controls (n = 26341) were matched by age, gender and geographic region.

Results

The risk of hip/femur fracture increased with current use of SSRIs (adjusted odds ratio (OR_adj) 2.35 [95% confidence interval (CI) 1.94–2.84]) and TCAs (ORadj 1.76 [95% CI 1.45–2.15]). The risk of hip/femur fracture declined rapidly after discontinuation of use. The risk of hip/femur fracture increased as the degree of 5-HTT inhibition of all anti-depressants increased from OR_adj 1.64 [95% CI 1.14–2.35] for drugs with low 5-HTT inhibition to OR_adj 2.31 [95% CI 1.94–2.76] for those with high 5-HTT inhibiting properties.

Conclusion

Current use of both SSRIs and TCAs increase hip/femur fracture risk. Further studies are needed to elucidate the mechanistic pathways and the relation with the underlying pathophysiology. Until then, the elevated fracture risk should be considered when prescribing anti-depressants.

Cole MG, Bellavance F, Mansour A (1999) Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry 156(8):1182–1189PubMed

Beekman AT et al (2002) The impact of depression on the well-being, disability and use of services in older adults: a longitudinal perspective. Acta Psychiatr Scand 105(1):20–27PubMedCrossRef

Cuijpers P, Smit F (2002) Excess mortality in depression: a meta-analysis of community studies. J Affect Disord 72(3):227–236PubMedCrossRef

Unutzer J et al (1997) Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. Jama 277(20):1618–1623PubMedCrossRef

Meijer WE et al (2004) Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 60(1):57–61PubMedCrossRef

Rosholm JU, Andersen M, Gram LF (2001) Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 56(12):923–929PubMedCrossRef

Martin RM et al (1997) General practitioners’ perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ 314(7081):646–651PubMed

Thapa PB et al (1998) Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339(13):875–882PubMedCrossRef

Ensrud KE et al (2003) Central nervous system active medications and risk for fractures in older women. Arch Intern Med 163(8):949–957PubMedCrossRef

10.

Gustafsson BI et al (2006) Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 97(6):1283–1291PubMedCrossRef

11.

Braithwaite RS, Col NF, Wong JB (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51(3):364–370PubMedCrossRef

12.

Haentjens P, Lamraski G, Boonen S (2005) Costs and consequences of hip fracture occurrence in old age: an economic perspective. Disabil Rehabil 27(18–19):1129–1141PubMedCrossRef

13.

Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307(6914):1248–1250PubMedCrossRef

14.

Roche JJ et al (2005) Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 331(7529):1374PubMedCrossRef

15.

Hubbard R et al (2003) Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 158(1):77–84PubMedCrossRef

16.

Liu B et al (1998) Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351(9112):1303–1307PubMedCrossRef

17.

Richards JB et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167(2):188–194PubMedCrossRef

18.

Battaglino R et al (2004) Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19(9):1420–1431PubMedCrossRef

19.

Bliziotes M et al (2002) The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2(3):291–295PubMed

20.

Bliziotes M et al (2006) Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39(6):1313–1321PubMedCrossRef

21.

Bliziotes MM et al (2001) Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29(5):477–486PubMedCrossRef

22.

Westbroek I et al (2001) Expression of serotonin receptors in bone. J Biol Chem 276(31):28961–28968PubMedCrossRef

23.

Gustafsson BI et al (2006) Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98(1):139–151PubMedCrossRef

24.

Vestergaard P et al (2008) Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 82:92–101PubMedCrossRef

25.

Herings R (1993) The PHARMO Drug Data Base: design and structure. PHARMO, a record linkage system for post-marketing surveillance of prescription drugs in The Netherlands. Doctoral thesis, Utrecht University, Utrecht, The Netherlands, pp 17–32

26.

Buurma H, De Smet PA, Egberts AC (2006) Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 29(8):723–732PubMedCrossRef

27.

Van der Schee E, Groenewegen PP, Friele RD (2006) Public trust in health care: a performance indicator? J Health Organ Manag 20(5):468–476PubMedCrossRef

28.

Van Staa TP et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993–1000PubMedCrossRef

29.

Herings RM et al (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49(1):115–119PubMedCrossRef

30.

Heerdink ER et al (1998) NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 158(10):1108–1112PubMedCrossRef

31.

WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health (2002) ATC classification index with DDDs 2002. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Nydalen

32.

Baldessarini R (2001) Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders. Chapter 19, in Goodman & Gilman’s. In: Hardman J, Limbird L, Goodman A (eds) The pharmacological basis of therapeutics. McGraw-Hill, New York, p 456

33.

Cherin P et al (1997) Risk of syncope in the elderly and consumption of drugs: a case–control study. J Clin Epidemiol 50(3):313–320PubMedCrossRef

34.

Laursen AL et al (1985) Paroxetine in the treatment of depression—a randomized comparison with amitriptyline. Acta Psychiatr Scand 71(3):249–255PubMedCrossRef

35.

Ensrud KE et al (2006) Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J Am Geriatr Soc 54(10):1508–1515PubMedCrossRef

36.

Newman AB et al (1997) Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the Cardiovascular Health Study. J Am Geriatr Soc 45(1):1–7PubMed

37.

Stone KL et al (2006) Self-reported sleep and nap habits and risk of falls and fractures in older women: the study of osteoporotic fractures. J Am Geriatr Soc 54(8):1177–1183PubMedCrossRef

38.

Warden SJ et al (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146(2):685–693PubMedCrossRef

39.

Cauley JA et al (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525–1537PubMedCrossRef

40.

Haney EM et al (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167(12):1246–1251PubMedCrossRef

41.

Diem SJ et al (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167(12):1240–1245PubMedCrossRef

42.

Manolagas SC (2000) Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 15(6):1001–1005PubMedCrossRef

43.

Weinstein RS et al (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102(2):274–282PubMedCrossRef

44.

Richelson E (2003) Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 64(Suppl 13):5–12PubMed

45.

Schneeweiss S, Wang PS (2004) Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharmacol 24(6):632–638PubMedCrossRef

46.

Whooley MA et al (1999) Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159(5):484–490PubMedCrossRef

Title: Use of anti-depressants and the risk of fracture of the hip or femur
Authors: M. W. M. van den Brand
M. M. Samson
S. Pouwels
T. P. van Staa
B. Thio
C. Cooper
H. G. M. Leufkens
A. C. G. Egberts
H. J. J. Verhaar
F. de Vries
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0849-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Use of anti-depressants and the risk of fracture of the hip or femur

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2009

Sex steroids during bone growth: a comparative study between mouse models for hypogonadal and senile osteoporosis

Osteoporosis in China

Use of anti-depressants and the risk of fracture of the hip or femur

Cross-geographic region differences in quality of life in women with and without vertebral fracture

Combining bone resorption markers and heel quantitative ultrasound to discriminate between fracture cases and controls

Fractures after nursing home admission: incidence and potential consequences